Eledon asset shows optimistic biomarker activity in ALS trial R&D, Therapeutics On Tuesday morning, Eledon Pharmaceuticals announced positive topline results from the company’s Phase IIa clinical trial evaluating tegoprubart in patients with amyotrophic lateral sclerosis (ALS). Read more May 31, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/05/BioSpacewheelchair5-31-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-05-31 12:16:202022-05-31 12:23:31Eledon asset shows optimistic biomarker activity in ALS trial
